MagForce AG
MagForce AG: MagForce USA Installs the First Clinical NanoActivator(R) in the USA
DGAP-News: MagForce AG / Key word(s): Miscellaneous MagForce USA Installs the First Clinical NanoActivator(R) in the USA Berlin, Germany, and Nevada, USA, November 23, 2015 – MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today that MagForce USA, Inc., MagForce AG’s US subsidiary, has successfully installed the first clinical NanoActivator(R) in the USA. This NanoActivator(R) is similar in design to the five NanoActivator(R) devices operating at University Hospitals in Germany applying NanoTherm(TM) Therapy for the treatment of Brain Tumors. However, the USA NanoActivator(R) has been modified to apply NanoTherm(TM) Therapy for the treatment of Prostate Cancer in addition to the treatment of Brain Tumors. The USA NanoActivator(R) is located in Seattle, Washington, near the University of Washington Medical Center, and will be utilized in the Focal Thermal Ablation Registriation Study for Prostate Cancer for which the Company has filed an Investigational Device Exemption (IDE) with The US Food and Drug Administration (FDA) in May 2015. About MagForce AG and MagForce USA, Inc. MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group’s proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc. NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit: www.magforce.com. Get to know our Technology: video (You Tube) Stay informed and subscribe to our mailing list.
Disclaimer This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. Contact:Anne Hennecke MC Services AG T +49 211 529252-22 F +49 211 529252-29 Email: anne.hennecke@mc-services.eu 2015-11-23 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MagForce AG | |
Max-Planck-Straße 3 | ||
12489 Berlin | ||
Germany | ||
Phone: | +49 (0)30 308 380 0 | |
Fax: | +49 (0)30 308 380 99 | |
E-mail: | info@magforce.com | |
Internet: | www.magforce.com | |
ISIN: | DE000A0HGQF5 | |
WKN: | A0HGQF | |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt | |
End of News | DGAP News Service |
415307 2015-11-23 |